MICROPORT: MICROPORT Heart Communication plans to merge with CRM Cayman to create a comprehensive cardiac solution platform
MicroPort announced that it has reached a merger agreement with CRM Cayman and its subsidiaries, which is planned to take effect on September 29, 2025. MicroPort Cardiac will issue new shares to CRM Cayman shareholders at a price of HKD 1.35 per share, and upon completion, CRM Cayman will become a wholly-owned subsidiary of MicroPort Cardiac. This move aims to establish a global cardiovascular product platform and enhance MicroPort Cardiac's research and development, manufacturing, and market capabilities in related fields
According to the announcement from MicroPort Scientific Corporation (00853), on September 29, 2025, CRM Cayman, MicroPort CardioFlow, and MicroPort CardioFlow CRM Limited (the merged subsidiary) entered into a merger agreement. The merged subsidiary is an exempted company registered in the Cayman Islands and is indirectly wholly owned by MicroPort CardioFlow.
Under the merger agreement, MicroPort CardioFlow will acquire CRM Cayman through the merged subsidiary in a merger. Upon the effectiveness of the merger, CRM Cayman will become an indirectly wholly-owned subsidiary of MicroPort CardioFlow, and as consideration, MicroPort CardioFlow will issue and allot several new shares to the shareholders of CRM Cayman (including the company's indirectly wholly-owned subsidiary MicroPort International Corp. Limited) at an issue price of HKD 1.35 per share. Upon completion of the merger, CRM Cayman and its subsidiaries will become indirect subsidiaries of MicroPort CardioFlow, and CRM Cayman, MicroPort CardioFlow, and their respective subsidiaries will continue to be subsidiaries of the company.
The announcement stated that the transaction described in the merger agreement aligns with the strategic development of MicroPort CardioFlow's business, helping to establish a globally positioned cardiac product platform that offers a diversified range of products and product pipelines, and achieves complementary synergies. These synergies will expand and diversify MicroPort CardioFlow's existing business, particularly in enhancing its product and product pipeline, research and development capabilities, manufacturing capabilities, distribution channels, and market expansion in structural heart disease and cardiac rhythm disease solutions
